Tokyo Tape
Sign in
← Nihon Chouzai

Quarterly report · Q1

3341.TEDINET S100OZY9
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥74.7bn2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥299.4bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥71.9bn2021-04-01 → 2021-06-30Cons.Net sales
Operating income¥892m2022-04-01 → 2022-06-30Cons.Operating income
Operating income¥936m2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income¥913m2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥6.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥993m2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥925m2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥993m2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥391m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.7bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥427m2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥391m2022-04-01 → 2022-06-30Cons.Profit loss
Net income¥427m2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥195.3bnat 2022-06-30Cons.Assets
Total assets¥178.8bnat 2022-03-31Cons.Assets
Total assets¥199.1bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥142.4bnat 2022-06-30Cons.Liabilities
Total liabilities¥125.9bnat 2022-03-31Cons.Liabilities
Net assets / equity¥52.9bnat 2022-06-30Cons.Net assets
Net assets / equity¥52.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥49.9bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥31.5bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥25.5bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥13.052022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥123.562021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥14.272021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio27.1%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio29.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio25.1%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥3.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥3.8bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥1.8bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥66.4bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥66.4bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥2.1bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3m
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥355m
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥10.0bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥6.3bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3.8bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥270m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥78.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥74.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥3.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥2.7bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥5.1bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥5.1bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥1.7bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥62.9bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥62.9bn
jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥1.9bn
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥2m
jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥278m
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥12.2bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥7.0bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥5.1bn
jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2021-04-01 → 2021-06-30¥451m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-06-30¥77.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-06-30¥71.9bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-06-30¥5.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-06-30¥2.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 352
ItemContextValueUnit
Profit loss attributable to owners of parentPrior1YTDDuration427000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration391000000JPY
Profit lossPrior1YTDDuration427000000JPY
Profit lossCurrentYTDDuration391000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration5000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration3000000JPY
Other comprehensive incomePrior1YTDDuration5000000JPY
Other comprehensive incomeCurrentYTDDuration3000000JPY
Comprehensive incomePrior1YTDDuration433000000JPY
Comprehensive incomeCurrentYTDDuration395000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration433000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration395000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember62912000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember7040000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember1899000000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember71851000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration71851000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember5118000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember2000000JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember5120000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-5120000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember62912000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember12158000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember1901000000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember76972000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-5120000000JPY
Net salesPrior1YTDDuration71851000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember1888000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember451000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember278000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember2618000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-1681000000JPY
Operating incomePrior1YTDDuration936000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember66375000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember6271000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q1r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember2063000000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember74709000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration74709000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember3756000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E05422-000MedicalProfessionalStaffingAndPlacementBusinessReportableSegmentsMember3000000JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember3759000000JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-3759000000JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E05422-000DispensingPharmacyBusinessReportableSegmentsMember66375000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E05422-000PharmaceuticalManufacturingAndSalesBusinessReportableSegmentsMember10027000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass